Management of advanced Hodgkin's disease in remission.
Patients with Hodgkin's disease (stage IIIB and IV) after being rendered with combination chemotherapy disease-free, were alternatively allocated to either a group receiving levamisole treatment (Decaris) or to a control group receiving no further therapy until there was evidence of recurrent disease. Laboratory examinations showed that impaired cell mediated immune responses found after termination of intensive chemotherapy were favourably influenced by levamisole treatment. In addition, the duration of remission seems to be longer in the levamisole treated group, although the limited number of patients in the study do not allow a definite conclusions to be drawn.
D002464:Cell Migration Inhibition; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007978:Levamisole / Q000627:therapeutic use*; D008213:Lymphocyte Activation; D012397:Rosette Formation; D013601:T-Lymphocytes / Q000276:immunology
D007074:Immunoglobulin G; D007978:Levamisole